Letermovir (LMV) Prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients With CMV Seropositive Donors: an Exploratory Study From Spanish GETH/TC Centers
N/A
This is an observational cohort study. Two cohort will be enrolled:
LMV co...
Status
Unknown
Location
Multiple Locations
Start Date
2024-03-30
Trial ID
NCT06211543
Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
PHASE3
The study evaluated the efficacy and safety of letermovir (MK-8228) for the...
MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)
PHASE3
This study aims to evaluate the safety, efficacy and pharmacokinetics (PK) ...
Status
Completed
Location
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital ( Site 0002)
Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)
PHASE3
The purpose of this study was to evaluate the safety and efficacy of leterm...